Navigation Links
Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS
Date:8/9/2013

NEW YORK, August 9, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), DaVita HealthCare Partners Inc. (NYSE: DVA), Celldex Therapeutics, Inc. (NASDAQ: CLDX), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), and VIVUS, Inc. (NASDAQ: VVUS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Regeneron Pharmaceuticals Inc. Research Report

On August 6, 2013, Regeneron Pharmaceuticals Inc. (Regeneron) reported its Q2 2013 financial results and provided an update on development programs. The Company's revenues increased 50.3% YoY to $457.6 million. Net income of $87.4 million or $0.79 per diluted share in Q2 2013, was higher as compared to net income of $76.7 million or $0.70 per diluted share in Q2 2012. Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, said, "We are pleased with the continued progress of EYLEA both in terms of commercialization and development in additional indications." He added, "Today, we reported positive Phase 3 data for EYLEA from the VIVID-DME and VISTA-DME trials in diabetic macular edema (DME). Based upon discussions with the U.S. Food & Drug Administration, we now plan to submit a regulatory application for approval for EYLEA in the DME indication in the U.S. later this year, approximately one year ahead of our previous plan." The Full Research Report on Regeneron Pharmaceuticals Inc. - including full detailed breakdown, analyst
'/>"/>

SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Financial Results, Earnings Schedules, Quarterly Dividends, and Top Rankings - Research Report on Quest Diagnostics, PerkinElmer, PAREXEL, Covance, and ICON
2. Innophos Holdings, Inc. Declares Quarterly Dividend
3. CVS Caremark Corporation Announces Quarterly Dividend
4. Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
5. AbbVie Declares Quarterly Dividend
6. Zimmer Announces Quarterly Dividend for Second Quarter of 2013
7. Correction Notice Of Press Release On Quarterly Dividend Announcement
8. Sigma-Aldrich Corporation Declares $0.215 Per Share Quarterly Dividend
9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2013 Sales And EPS Of $675 Million And $1.01, Respectively, Both Record Quarterly Highs. Reaffirms Full Year 2013 Diluted Adjusted EPS Outlook Of $4.10 To $4.20.
10. Par Pharmaceutical Announces Quarterly Conference Call
11. UPDATE: Zimmer Announces 11% Increase in Quarterly Dividend for First Quarter of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... gefragt. Das Problem dabei ist, dass ... mit der Kompetenz zu teilen. Es ... deshalb freuen wir uns umso mehr, dass es ... ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit einem ...
(Date:10/17/2014)... 2014 With the recent changes in ... come across several challenges in creating and utilizing ... The Medical Affairs Consortium ... providing benchmarking and best practices across critical Medical ... service composed of three stages: 1) member-driven topic ...
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Antibacterial Products aimed at reducing cross contamination ... infections ... Corporation,announced today the SILVER SEAL(TM) family of antibacterial products for,infection ... and Mouse. According to the company, the,SILVER SEAL(TM) Keyboard and ...
... - Once Granted by the European Commission, ATRIPLA Would Represent the, First ... ... Union -, PRINCETON, N.J., FOSTER CITY, Calif. and WHITEHOUSE STATION, N.J., ... GILD ) and Merck & Co., Inc. (NYSE: MRK ),announced ...
Cached Medicine Technology:Seal Shield Launches World's First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control 2Seal Shield Launches World's First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control 3European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 2European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 3European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 4European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 5European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 6European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 7European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 8European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 9European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 10
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Hastings and ... 30 years of service throughout the greater Phoenix area ... legal representation with regard to catastrophic automobile accidents. Statistics ... the country and throughout Arizona. As such, Hastings and ... for legal representation for those who have been injured ...
(Date:10/19/2014)... This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ... late-stage and discontinued projects. , Partial Seizures are ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
(Date:10/19/2014)... that causes inflammation in the spinal joints and ... ancient Egyptian royal families. Now a new study ... journal of the American College of Rheumatology (ACR), ... condition called diffuse idiopathic skeletal hyperostosis (DISH) in ... 20th Dynasties. , Ankylosing spondylitis is a ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... 2008) Two Mayo Clinic researchers who study the role ... the formation of kidney stones, will lead a symposium on ... symposium will take place April 8 at the Experimental Biology ... smaller than the bacteria, E. coli, but recent advances in ...
... Group And Digital Peach Interactive Group Unite To ... Networks To Improve Women,s Healthcare, NEW YORK, ... company,comprised of multiple specialized and related businesses focused ... today a,unique partnership that will engage, connect and ...
... Leading Maker of Rugged Computers Donates GoBook(R) XR-1 Notebooks to ... Support ... General Dynamics,Itronix, an industry leading maker of rugged notebook ... Expedition,2008: Fighting Malaria on the "River of Life." The XR-1 ...
... from overweight, high blood pressure and metabolic disturbances ... is the result of a study with almost ... of the Deutsches rzteblatt International (Dtsch Arztebl Int ... The so-called metabolic syndrome describes a typical constellation ...
... finds having autistic child shrinks family income by 14% , , ... additional light on two different aspects of autism: One tried ... while the other looked at the financial toll that having ... were expected to be published in the April issue of ...
... 2008 MedCath,Corporation (Nasdaq: MDTH ) announced ... percent interest in a joint venture known as ... venture provides cardiac,catheterization lab services to Yuma Regional ... Management and Service Agreement with,the Hospital., The ...
Cached Medicine News:Health News:Symposium to explore role nanoparticles may play in disease 2Health News:Kinetix Creates Innovative Online Model to Engage and Educate Healthcare Professionals 2Health News:General Dynamics Itronix Donates Computers to Humanitarian Expedition Fighting Malaria in Africa 2Health News:General Dynamics Itronix Donates Computers to Humanitarian Expedition Fighting Malaria in Africa 3Health News:Very Premature Babies Show Raised Risk for Autism 2Health News:Very Premature Babies Show Raised Risk for Autism 3Health News:MedCath Announces Acquisition of Ownership in Arizona Cath Lab 2
Selute Picotip Atrial-J steroid eluting passive fixation lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: